Description
Unlike single- or dual-receptor incretin compounds, retatrutide’s triple-agonist design allows researchers to study the interplay between GLP-1-driven appetite signaling, GIP-mediated insulin sensitivity, and glucagon receptor-linked thermogenesis within a single experimental model. Investigators use this compound to examine energy expenditure, lipid metabolism, and hepatic fat pathways in cell-based and animal research systems, and to compare multi-receptor agonism against mono- and dual-agonist incretin peptides.
Research Applications
- Multi-receptor incretin pathway studies (GLP-1R / GIPR / GCGR)
- Energy expenditure and thermogenesis research
- Hepatic lipid metabolism models
- Comparative studies against GLP-1 and GIP/GLP-1 dual agonists
- Receptor desensitization and chronic exposure research
Disclaimer For laboratory research use only. Not for human consumption, clinical use, veterinary use, diagnosis, or therapeutic application.





Reviews
There are no reviews yet.